# Dermtest OU

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dermtest-ou

- Industry: Healthcare Specialists
- Headquarters: Tallinn, Estonia
- Website: www.dermtest.com
- Total disclosed funding: $0M
- Latest round: Seed (Oct 3, 2016)
- Investors on record: 1

## About

Dermtest OU develops a digital toolbox for skin and wound care, focusing on enhancing collaboration between healthcare providers. Their platform enables early detection and efficient consultation for skin-related concerns.Founded in 2013 in Tallinn, Estonia, Dermtest OU specializes in digital solutions for skin care, leveraging technology to improve healthcare delivery. The company has not undergone any known pivots in its strategy. Dermtest OU was co-founded by Priit Kruus and Riina Hallik, with Priit Kruus serving as the CEO. Since its inception, the company has raised EUR 20,000 during its SEED funding round on October 3, 2016, from Startupbootcamp FinTech & CyberSecurity. This funding has contributed to their total raised amount of EUR 20,000.Dermtest offers a comprehensive digital toolbox focused on skin and wound care, designed specifically for healthcare professionals. The company's core product facilitates collaboration between local doctors and specialists, enabling early detection and consultation for suspicious moles. Key features include clinical photo management, which allows healthcare providers to capture, securely archive, and share images with colleagues for teleconsultations or referrals. This system integrates seamlessly with existing Electronic Health Records (EHRs) but can also function independently. Dermtest has established partnerships with over 70 hospitals and clinics, including the five largest public hospitals in Estonia. The service caters primarily to the Estonian healthcare market, effectively covering all regions with a significant user base of general practitioners and specialists employing teledermatoscopy technology to connect dermatological expertise to approximately 1.3 million individuals.In 2023, Dermtest reported a revenue of EUR 130,163.4 and an EBITDA of EUR 102,362.1. The company generates revenue through partnerships with healthcare institutions and subscription-based services tailored for medical professionals, involving licensing agreements with hospitals and clinics that utilize Dermtest's digital tools for skin cancer detection and chronic skin disease monitoring. The pricing structure accommodates various needs, emphasizing a B2B approach to ensure compliance with privacy protection and secure access rights management.Dermtest plans to enhance its product offering with new features and tools aimed at improving dermatological care, although specific product release dates are not detailed. The company is exploring expansion into new markets beyond Estonia, targeting broader European healthcare sectors by the end of 2024. The recent funding of EUR 20,000 will support these initiatives, facilitating the development of new products and expanding their reach within the healthcare industry.

## Funding rounds

- Seed, Oct 3, 2016, $0M — Startupbootcamp

## Investors

- Startupbootcamp (https://capitalatlas.ai/funds/startupbootcamp) — Seed